Abstract
Six antitumor platinum compounds were used in combination with cyclophosphamide (CY) plus one of five other antitumor drugs in the treatment of advanced (Day 3) L1210 leukemia in (C57BL/6 X DBA/2)F1 mice. The combination of CY with a platinum compound yielded a collective cure rate of 24%; the addition of a third drug to the dual regimen increased the collective cure rate to 55%. The most effective drugs when used in combination with platinum compounds plus CY were, in increasing order of efficacy, 5-fluorouracil, hydroxyurea, and methotrexate. No toxic deaths occurred with any regimen at the dose levels used.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use*
-
Cell Division
-
Cell Survival / drug effects
-
Cisplatin / analogs & derivatives
-
Cisplatin / therapeutic use*
-
Cyclophosphamide / therapeutic use
-
Drug Therapy, Combination
-
Fluorouracil / therapeutic use
-
Hydroxyurea / therapeutic use
-
Leukemia L1210 / drug therapy*
-
Leukemia L1210 / pathology
-
Methotrexate / therapeutic use
-
Mice
-
Mice, Inbred C57BL
-
Mice, Inbred DBA
Substances
-
Antineoplastic Agents
-
Cyclophosphamide
-
Cisplatin
-
Fluorouracil
-
Hydroxyurea
-
Methotrexate